vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Dominari Holdings Inc. is the larger business by last-quarter revenue ($30.1M vs $20.6M, roughly 1.5× Entrada Therapeutics, Inc.). Entrada Therapeutics, Inc. runs the higher net margin — -84.4% vs -438.1%, a 353.7% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs -65.2%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 6.4%).
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
DOMH vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $20.6M |
| Net Profit | $-131.8M | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | -8.9% | -106.0% |
| Net Margin | -438.1% | -84.4% |
| Revenue YoY | 220.4% | -65.2% |
| Net Profit YoY | -12426.2% | -173.8% |
| EPS (diluted) | $-6.94 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | — | ||
| Q3 25 | $50.8M | — | ||
| Q2 25 | $34.1M | — | ||
| Q1 25 | $8.1M | $20.6M | ||
| Q4 24 | $9.4M | $37.4M | ||
| Q3 24 | $4.0M | $19.6M | ||
| Q2 24 | $6.2M | $94.7M | ||
| Q1 24 | $1.4M | $59.1M |
| Q4 25 | $-131.8M | — | ||
| Q3 25 | $125.2M | — | ||
| Q2 25 | $16.6M | — | ||
| Q1 25 | $-32.5M | $-17.3M | ||
| Q4 24 | $1.1M | $1.1M | ||
| Q3 24 | $-4.2M | $-14.0M | ||
| Q2 24 | $-6.1M | $55.0M | ||
| Q1 24 | $-5.4M | $23.5M |
| Q4 25 | -8.9% | — | ||
| Q3 25 | -3.1% | — | ||
| Q2 25 | -57.0% | — | ||
| Q1 25 | -394.6% | -106.0% | ||
| Q4 24 | 0.4% | -15.7% | ||
| Q3 24 | -79.1% | -110.7% | ||
| Q2 24 | -44.3% | 56.4% | ||
| Q1 24 | -205.2% | 35.7% |
| Q4 25 | -438.1% | — | ||
| Q3 25 | 246.4% | — | ||
| Q2 25 | 48.7% | — | ||
| Q1 25 | -400.5% | -84.4% | ||
| Q4 24 | 11.4% | 3.0% | ||
| Q3 24 | -104.2% | -71.7% | ||
| Q2 24 | -99.1% | 58.1% | ||
| Q1 24 | -398.0% | 39.7% |
| Q4 25 | $-6.94 | — | ||
| Q3 25 | $7.27 | — | ||
| Q2 25 | $1.12 | — | ||
| Q1 25 | $-3.02 | $-0.42 | ||
| Q4 24 | $0.21 | $-0.20 | ||
| Q3 24 | $-0.67 | $-0.35 | ||
| Q2 24 | $-1.01 | $1.55 | ||
| Q1 24 | $-0.91 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $417.3M |
| Total Assets | $112.9M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | — | ||
| Q3 25 | $176.2M | — | ||
| Q2 25 | $28.2M | — | ||
| Q1 25 | $18.9M | $67.8M | ||
| Q4 24 | $8.2M | $101.2M | ||
| Q3 24 | $7.2M | $78.0M | ||
| Q2 24 | $12.1M | $185.3M | ||
| Q1 24 | $7.1M | $68.4M |
| Q4 25 | $69.4M | — | ||
| Q3 25 | $210.2M | — | ||
| Q2 25 | $88.6M | — | ||
| Q1 25 | $42.4M | $417.3M | ||
| Q4 24 | $39.9M | $428.7M | ||
| Q3 24 | $38.3M | $422.4M | ||
| Q2 24 | $42.4M | $429.9M | ||
| Q1 24 | $47.7M | $269.4M |
| Q4 25 | $112.9M | — | ||
| Q3 25 | $223.4M | — | ||
| Q2 25 | $109.3M | — | ||
| Q1 25 | $52.3M | $486.5M | ||
| Q4 24 | $47.1M | $526.3M | ||
| Q3 24 | $43.4M | $554.6M | ||
| Q2 24 | $49.1M | $582.0M | ||
| Q1 24 | $52.2M | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | — | ||
| Q3 25 | $-4.9M | — | ||
| Q2 25 | $-353.0K | — | ||
| Q1 25 | $1.2M | $-38.5M | ||
| Q4 24 | $-16.7M | $-31.6M | ||
| Q3 24 | $-4.7M | $-24.3M | ||
| Q2 24 | $1.4M | $39.8M | ||
| Q1 24 | $-8.6M | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | — | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | — | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | — | 41.0% | ||
| Q1 24 | — | -44.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
TRDA
Segment breakdown not available.
